Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study

To evaluate treatment results of Rifampicin (R) resistant Isoniazid (H) susceptible tuberculosis cases. Cohort analysis of twenty-three H susceptible R resistant tuberculosis cases started treatment in 1985-2004 at Fukujuji Hospital, by the retrospective review. Three cases became Multi-drug resista...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Kekkaku 2007-02, Vol.82 (2), p.95-101
Hauptverfasser: Yoshiyama, Takashi, Ogata, Hideo, Ito, Kunihiko, Aono, Akio, Wada, Masako
Format: Artikel
Sprache:jpn
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 101
container_issue 2
container_start_page 95
container_title Kekkaku
container_volume 82
creator Yoshiyama, Takashi
Ogata, Hideo
Ito, Kunihiko
Aono, Akio
Wada, Masako
description To evaluate treatment results of Rifampicin (R) resistant Isoniazid (H) susceptible tuberculosis cases. Cohort analysis of twenty-three H susceptible R resistant tuberculosis cases started treatment in 1985-2004 at Fukujuji Hospital, by the retrospective review. Three cases became Multi-drug resistant tuberculosis (MDR TB), seventeen cases were cured, two cases died, and one case transferred out. One started treatment with HR became MDR, one of the two started treatment with HR+ Ethambutol (E) became MDR and one of them was cured, eight among ten cases started treatment with HR+Pyrazinamide + (E or Streptomycine (S)) were cured, one among the ten died and one among the ten transferred out, one started treatment with RZE was cured, three among the five cases started treatment with three effective drugs without Z were cured, one among the five died, one among the five became MDR. Three cases started treatment with four effective drugs were cured. Among the nineteen cases continued treatment for more than six months, ten cases treated with four or five effective drugs for at least two months were cured, two cases of nine cases treated with three drugs or less became MDR, seven of the nine cases were cured. Among the same nineteen cases, eleven cases not treated with two or less effective drugs were cured, one case treated with two or less effective drugs for six months became MDR and one of them treated with one or two effective drug for one to three months became MDR and some were cured. The used drugs were H, E, Pyrazinamide, Streptomycin, Kanamycin, Ethionamide and New Quinolones. The duration of treatment of cured cases were eleven to twelve months in 3 cases, twelve to eighteen months in 3 cases, eighteen to twenty-four months in 8 cases and more than two years in 3 cases. If the starting regimen is HRZE, we can cure R resistant H susceptible tuberculosis by the use of four effective drugs for more than two months and at least three effective drugs with the total duration of treatment for twelve to twenty-four months.
doi_str_mv 10.11400/kekkaku1923.82.95
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70298847</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70298847</sourcerecordid><originalsourceid>FETCH-LOGICAL-j244t-6021fa8fa0c17b792ecc7a07ca1b163bdecd72a6680eedfad79a94155db4fda23</originalsourceid><addsrcrecordid>eNo10EtLAzEUBeAsFFtq_4ALyUpacGpencwspVgtFBWp6-HmMRjn6SRZ1F_viHV1F-fjcLgIXVGyolQQclfZqoIq0pzxVcZW-foMTQlhLMmlTCdo7r1ThJBcEJ6JCzShkkvOaTZF_WGwEBrbBjxYH-vgcVfiwZXQ9E67Fi_etq_L38z5AKNyvmsdfDuDF7vnpyX20WvbB6dqi0NUdtCx7kZ8iwF_dL53AWqswFuDfYjmeInOS6i9nZ_uDL1vHw6bp2T_8rjb3O-TTyZESFLCaAlZCURTqWTOrNYSiNRAFU25MlYbySBNM2KtKcHIHHJB12ujRGmA8Rm6-evth-4rWh-Kxo1L6xpa20VfSMLyLBNyhNcnGFVjTdEProHhWPz_iP8As3Brzg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70298847</pqid></control><display><type>article</type><title>Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study</title><source>J-STAGE Free</source><source>MEDLINE</source><creator>Yoshiyama, Takashi ; Ogata, Hideo ; Ito, Kunihiko ; Aono, Akio ; Wada, Masako</creator><creatorcontrib>Yoshiyama, Takashi ; Ogata, Hideo ; Ito, Kunihiko ; Aono, Akio ; Wada, Masako</creatorcontrib><description>To evaluate treatment results of Rifampicin (R) resistant Isoniazid (H) susceptible tuberculosis cases. Cohort analysis of twenty-three H susceptible R resistant tuberculosis cases started treatment in 1985-2004 at Fukujuji Hospital, by the retrospective review. Three cases became Multi-drug resistant tuberculosis (MDR TB), seventeen cases were cured, two cases died, and one case transferred out. One started treatment with HR became MDR, one of the two started treatment with HR+ Ethambutol (E) became MDR and one of them was cured, eight among ten cases started treatment with HR+Pyrazinamide + (E or Streptomycine (S)) were cured, one among the ten died and one among the ten transferred out, one started treatment with RZE was cured, three among the five cases started treatment with three effective drugs without Z were cured, one among the five died, one among the five became MDR. Three cases started treatment with four effective drugs were cured. Among the nineteen cases continued treatment for more than six months, ten cases treated with four or five effective drugs for at least two months were cured, two cases of nine cases treated with three drugs or less became MDR, seven of the nine cases were cured. Among the same nineteen cases, eleven cases not treated with two or less effective drugs were cured, one case treated with two or less effective drugs for six months became MDR and one of them treated with one or two effective drug for one to three months became MDR and some were cured. The used drugs were H, E, Pyrazinamide, Streptomycin, Kanamycin, Ethionamide and New Quinolones. The duration of treatment of cured cases were eleven to twelve months in 3 cases, twelve to eighteen months in 3 cases, eighteen to twenty-four months in 8 cases and more than two years in 3 cases. If the starting regimen is HRZE, we can cure R resistant H susceptible tuberculosis by the use of four effective drugs for more than two months and at least three effective drugs with the total duration of treatment for twelve to twenty-four months.</description><identifier>ISSN: 0022-9776</identifier><identifier>DOI: 10.11400/kekkaku1923.82.95</identifier><identifier>PMID: 17373318</identifier><language>jpn</language><publisher>Japan</publisher><subject>Adult ; Aged ; Antibiotics, Antitubercular - pharmacology ; Antitubercular Agents - pharmacology ; Antitubercular Agents - therapeutic use ; Drug Administration Schedule ; Drug Resistance, Bacterial ; Female ; Humans ; Isoniazid - pharmacology ; Male ; Middle Aged ; Mycobacterium tuberculosis - drug effects ; Rifampin - pharmacology ; Tuberculosis - drug therapy ; Tuberculosis, Multidrug-Resistant</subject><ispartof>Kekkaku, 2007-02, Vol.82 (2), p.95-101</ispartof><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17373318$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoshiyama, Takashi</creatorcontrib><creatorcontrib>Ogata, Hideo</creatorcontrib><creatorcontrib>Ito, Kunihiko</creatorcontrib><creatorcontrib>Aono, Akio</creatorcontrib><creatorcontrib>Wada, Masako</creatorcontrib><title>Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study</title><title>Kekkaku</title><addtitle>Kekkaku</addtitle><description>To evaluate treatment results of Rifampicin (R) resistant Isoniazid (H) susceptible tuberculosis cases. Cohort analysis of twenty-three H susceptible R resistant tuberculosis cases started treatment in 1985-2004 at Fukujuji Hospital, by the retrospective review. Three cases became Multi-drug resistant tuberculosis (MDR TB), seventeen cases were cured, two cases died, and one case transferred out. One started treatment with HR became MDR, one of the two started treatment with HR+ Ethambutol (E) became MDR and one of them was cured, eight among ten cases started treatment with HR+Pyrazinamide + (E or Streptomycine (S)) were cured, one among the ten died and one among the ten transferred out, one started treatment with RZE was cured, three among the five cases started treatment with three effective drugs without Z were cured, one among the five died, one among the five became MDR. Three cases started treatment with four effective drugs were cured. Among the nineteen cases continued treatment for more than six months, ten cases treated with four or five effective drugs for at least two months were cured, two cases of nine cases treated with three drugs or less became MDR, seven of the nine cases were cured. Among the same nineteen cases, eleven cases not treated with two or less effective drugs were cured, one case treated with two or less effective drugs for six months became MDR and one of them treated with one or two effective drug for one to three months became MDR and some were cured. The used drugs were H, E, Pyrazinamide, Streptomycin, Kanamycin, Ethionamide and New Quinolones. The duration of treatment of cured cases were eleven to twelve months in 3 cases, twelve to eighteen months in 3 cases, eighteen to twenty-four months in 8 cases and more than two years in 3 cases. If the starting regimen is HRZE, we can cure R resistant H susceptible tuberculosis by the use of four effective drugs for more than two months and at least three effective drugs with the total duration of treatment for twelve to twenty-four months.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibiotics, Antitubercular - pharmacology</subject><subject>Antitubercular Agents - pharmacology</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Drug Administration Schedule</subject><subject>Drug Resistance, Bacterial</subject><subject>Female</subject><subject>Humans</subject><subject>Isoniazid - pharmacology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Rifampin - pharmacology</subject><subject>Tuberculosis - drug therapy</subject><subject>Tuberculosis, Multidrug-Resistant</subject><issn>0022-9776</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo10EtLAzEUBeAsFFtq_4ALyUpacGpencwspVgtFBWp6-HmMRjn6SRZ1F_viHV1F-fjcLgIXVGyolQQclfZqoIq0pzxVcZW-foMTQlhLMmlTCdo7r1ThJBcEJ6JCzShkkvOaTZF_WGwEBrbBjxYH-vgcVfiwZXQ9E67Fi_etq_L38z5AKNyvmsdfDuDF7vnpyX20WvbB6dqi0NUdtCx7kZ8iwF_dL53AWqswFuDfYjmeInOS6i9nZ_uDL1vHw6bp2T_8rjb3O-TTyZESFLCaAlZCURTqWTOrNYSiNRAFU25MlYbySBNM2KtKcHIHHJB12ujRGmA8Rm6-evth-4rWh-Kxo1L6xpa20VfSMLyLBNyhNcnGFVjTdEProHhWPz_iP8As3Brzg</recordid><startdate>200702</startdate><enddate>200702</enddate><creator>Yoshiyama, Takashi</creator><creator>Ogata, Hideo</creator><creator>Ito, Kunihiko</creator><creator>Aono, Akio</creator><creator>Wada, Masako</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200702</creationdate><title>Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study</title><author>Yoshiyama, Takashi ; Ogata, Hideo ; Ito, Kunihiko ; Aono, Akio ; Wada, Masako</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j244t-6021fa8fa0c17b792ecc7a07ca1b163bdecd72a6680eedfad79a94155db4fda23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>jpn</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibiotics, Antitubercular - pharmacology</topic><topic>Antitubercular Agents - pharmacology</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Drug Administration Schedule</topic><topic>Drug Resistance, Bacterial</topic><topic>Female</topic><topic>Humans</topic><topic>Isoniazid - pharmacology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Rifampin - pharmacology</topic><topic>Tuberculosis - drug therapy</topic><topic>Tuberculosis, Multidrug-Resistant</topic><toplevel>online_resources</toplevel><creatorcontrib>Yoshiyama, Takashi</creatorcontrib><creatorcontrib>Ogata, Hideo</creatorcontrib><creatorcontrib>Ito, Kunihiko</creatorcontrib><creatorcontrib>Aono, Akio</creatorcontrib><creatorcontrib>Wada, Masako</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Kekkaku</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshiyama, Takashi</au><au>Ogata, Hideo</au><au>Ito, Kunihiko</au><au>Aono, Akio</au><au>Wada, Masako</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study</atitle><jtitle>Kekkaku</jtitle><addtitle>Kekkaku</addtitle><date>2007-02</date><risdate>2007</risdate><volume>82</volume><issue>2</issue><spage>95</spage><epage>101</epage><pages>95-101</pages><issn>0022-9776</issn><abstract>To evaluate treatment results of Rifampicin (R) resistant Isoniazid (H) susceptible tuberculosis cases. Cohort analysis of twenty-three H susceptible R resistant tuberculosis cases started treatment in 1985-2004 at Fukujuji Hospital, by the retrospective review. Three cases became Multi-drug resistant tuberculosis (MDR TB), seventeen cases were cured, two cases died, and one case transferred out. One started treatment with HR became MDR, one of the two started treatment with HR+ Ethambutol (E) became MDR and one of them was cured, eight among ten cases started treatment with HR+Pyrazinamide + (E or Streptomycine (S)) were cured, one among the ten died and one among the ten transferred out, one started treatment with RZE was cured, three among the five cases started treatment with three effective drugs without Z were cured, one among the five died, one among the five became MDR. Three cases started treatment with four effective drugs were cured. Among the nineteen cases continued treatment for more than six months, ten cases treated with four or five effective drugs for at least two months were cured, two cases of nine cases treated with three drugs or less became MDR, seven of the nine cases were cured. Among the same nineteen cases, eleven cases not treated with two or less effective drugs were cured, one case treated with two or less effective drugs for six months became MDR and one of them treated with one or two effective drug for one to three months became MDR and some were cured. The used drugs were H, E, Pyrazinamide, Streptomycin, Kanamycin, Ethionamide and New Quinolones. The duration of treatment of cured cases were eleven to twelve months in 3 cases, twelve to eighteen months in 3 cases, eighteen to twenty-four months in 8 cases and more than two years in 3 cases. If the starting regimen is HRZE, we can cure R resistant H susceptible tuberculosis by the use of four effective drugs for more than two months and at least three effective drugs with the total duration of treatment for twelve to twenty-four months.</abstract><cop>Japan</cop><pmid>17373318</pmid><doi>10.11400/kekkaku1923.82.95</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-9776
ispartof Kekkaku, 2007-02, Vol.82 (2), p.95-101
issn 0022-9776
language jpn
recordid cdi_proquest_miscellaneous_70298847
source J-STAGE Free; MEDLINE
subjects Adult
Aged
Antibiotics, Antitubercular - pharmacology
Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
Drug Administration Schedule
Drug Resistance, Bacterial
Female
Humans
Isoniazid - pharmacology
Male
Middle Aged
Mycobacterium tuberculosis - drug effects
Rifampin - pharmacology
Tuberculosis - drug therapy
Tuberculosis, Multidrug-Resistant
title Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T11%3A51%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20results%20of%20rifampicin%20(RFP)%20resistant%20isoniazid%20(INH)%20susceptible%20tuberculosis,%20a%20hospital%20based%20study&rft.jtitle=Kekkaku&rft.au=Yoshiyama,%20Takashi&rft.date=2007-02&rft.volume=82&rft.issue=2&rft.spage=95&rft.epage=101&rft.pages=95-101&rft.issn=0022-9776&rft_id=info:doi/10.11400/kekkaku1923.82.95&rft_dat=%3Cproquest_pubme%3E70298847%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70298847&rft_id=info:pmid/17373318&rfr_iscdi=true